お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:慢性閉塞性肺疾患 (COPD) - 世界の治療薬市場の予測と分析
市場調査レポート
商品コード
537176

慢性閉塞性肺疾患 (COPD) - 世界の治療薬市場の予測と分析

Chronic Obstructive Pulmonary Disease: Global Drug Forecast and Market Analysis to 2028

出版日: | 発行: GlobalData | ページ情報: 英文 154 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円
慢性閉塞性肺疾患 (COPD) - 世界の治療薬市場の予測と分析
出版日: 2020年03月30日
発行: GlobalData
ページ情報: 英文 154 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の慢性閉塞性肺疾患 (COPD) 治療薬市場について分析し、疾患の概要や疫学的背景、有病者数の動向見通し、治験の進行状況、上市済み/治験ちゅの主な治療薬、現在の市場のアンメットニーズ、主要企業のプロファイル、全世界/主要国の市場動向見通しなどを調査・推計しております。

第1章 目次

第2章 エグゼクティブ・サマリー

第3章 イントロダクション

第4章 疾患概要

  • 病因と病態生理
    • 病因
    • 病態生理
  • 分類と病期
  • 症状
  • ぜんそくとCOPDの合併症
  • 生活の質 (QoL)

第5章 疫学

  • 疾患の背景事情
  • リスク要因と併存症
  • 世界の動向実績
  • 予測手法
    • 情報源
    • 予測の前提条件と手法
    • 有病者総数
    • 受診済み有病者数
    • 受診済み有病者数:重症度別
  • COPDの疫学的予測 (通算11年間分)
    • COPDの有病者総数
    • COPDの有病者数:年齢別
    • COPDの有病者数:男女別
    • COPDの受診済み有病者数
    • COPDの受診済み有病者数:年齢別
    • COPDの受診済み有病者数:男女別
    • COPDの受診済み有病者数:重症度別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第6章 疾患管理

  • 診断・治療の概要
    • 診断
    • 治療のガイドライン
    • RAの治療用の代表的な処方薬
    • 臨床診療
  • 米国
  • 欧州主要5ヶ国 (5EU)
  • 日本
  • オーストラリア

第7章 競合評価

  • 概要
  • 長期間作用型β2作動薬
    • Onbrez Breezhaler (マレイン酸インダカテロール)
    • Serevent Diskus (キシナホ酸塩サルメテロール)
    • Striverdi Respimat (塩酸オロダテロール)
    • Branded formoterol (フマル酸ホルモテロール)
    • Brovana (酒石酸アルフォルモテロール)
  • 長期間作用型ムスカリン拮抗剤
    • Spiriva (臭化チオトロピウム)
    • Tudorza Pressair (臭化アクリジニウム)
    • Seebri Breezhaler (グリコピロレート)
    • Incruse Ellipta (臭化ウメクリジニウム)
  • LABA/LAMA多剤混合薬 (FDC)
    • Ultibro Breezhaler (グリコピロレート+マレイン酸インダカテロール)
    • Anoro Ellipta (臭化ウメクリジニウム+トリフェニル酢酸ビランテロール)
    • Duaklir Genuair (臭化アクリジニウム+フマル酸ホルモテロール)
    • Stiolto Respimat (塩酸オロダテロール+臭化チオトロピウム)
    • Bevespi Aerosphere (フマル酸ホルモテロール+グリコピロレート)
  • 吸入コルチコステロイド/LABA多剤混合薬
    • Advair Diskus (フロ酸フルチカゾン+キシナホ酸サルメテロール)
    • Symbicort (ブデソニド+フマル酸ホルモテロール)
    • Breo Ellipta (フロ酸フルチカゾン+トリフェニル酢酸ビランテロール)
    • Fostair (ジプロピオン酸ベクロメタゾン+フマル酸ホルモテロール)
  • フォスフォジエステラーゼ (PDE) 阻害剤
    • Daliresp (ロルフミラスト)
    • その他のPDE4阻害剤
  • 短期間作用型β2作動薬
    • 概要
  • 短期間作用型ムスカリン拮抗剤
    • 概要
  • SABA/SAMA多剤混合薬
    • 概要
  • オフラベル治療薬
    • ぜんそく治療薬
  • その他の治療クラス

第8章 アンメットニーズおよび市場機会の分析

  • 概要
  • 症状に対するステークホルダーの認識
    • アンメットニーズ
    • ギャップ分析
    • 市場機会
  • 肺活量測定のアクセス・訓練の増加
  • COPDの進行をくい止める治療薬
  • 特有の表現型の治療薬向けバイオマーカーの特定
  • 呼吸リハビリサービスへのアクセスの不十分さ
  • 禁煙プログラム

第9章 パイプライン評価

  • 概要
  • 治験マッピング
    • クラス別
  • 治験中の有望な医薬品
  • LAMA (長時間作用型コリン薬)
    • SUN-101 (グリコピロレート)
    • Revefenacin
  • ICS/LABA/LAMA多剤混合薬 (FDC)
    • CHF-5993 (ジプロピオン酸ベクロメタゾン+フマル酸ホルモテロール+グリコピロレート)
    • PT-010 (ブデソニド+フマル酸ホルモテロール+グリコピロレート)
    • FF/UMEC/VI (フロ酸フルチカゾン+臭化ウメクリジニウム+トリフェニル酢酸ビランテロール)
  • IL-5阻害剤
    • Nucala (メポリズマブ)
    • ベンラリズマブ
  • その他の治験中の医薬品

第10章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • AstraZeneca
    • Boehringer Ingelheim
    • Chiesi
    • GlaxoSmithKline
    • Novartis
    • Sunovion

第11章 市場予測

  • 世界市場
    • 患者人口の予測 (mMRC方式/CAT方式)
    • 近年の主な動き
    • 市場促進・抑制要因
  • 米国
  • 欧州主要5ヶ国 (5EU)
  • 日本
  • オーストラリア

第12章 付録

図表

List of Tables

  • Table 1: COPD: Key Metrics in the 7MM
  • Table 2: GOLD Criteria for the Classification of COPD, 2018
  • Table 3: Symptoms of COPD
  • Table 4: Modified mMRC Dyspnea Scale
  • Table 5: Risk Factors and Comorbidities for COPD
  • Table 6: Treatment Guidelines for COPD
  • Table 7: Country Profile - US, 2018
  • Table 8: Region Profile - 5EU, 2018
  • Table 9: Country Profile - Japan, 2018
  • Table 10: Leading Treatments for COPD, 2018
  • Table 11: Comparison of Therapeutic Classes in Development for COPD, 2018-2028
  • Table 12: AstraZeneca's COPD Portfolio Assessment, 2019
  • Table 13: Chiesi's COPD Portfolio Assessment, 2019
  • Table 14: GSK's COPD Portfolio Assessment, 2019
  • Table 15: Novartis' COPD Portfolio Assessment, 2019
  • Table 16: Sunovion's COPD Portfolio Assessment, 2019
  • Table 17: Sunovion's COPD Portfolio Assessment, 2019
  • Table 18: Theravance's COPD Portfolio Assessment, 2019
  • Table 19: COPD Market - Global Drivers and Barriers, 2018-2028
  • Table 20: Key Events Impacting Sales for COPD in the US, 2018-2028
  • Table 21: COPD Market - Drivers and Barriers in the US, 2018-2028
  • Table 22: Key Events Impacting Sales for COPD in the 5EU, 2018-2028
  • Table 23: COPD Market - Drivers and Barriers in the 5EU, 2018-2028
  • Table 24: Key Events Impacting Sales for COPD in the Japan, 2018-2028
  • Table 25: COPD Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 26: Historical and projected launch dates for COPD across the 7MM, 2018-2028
  • Table 27: Historical and projected expiry dates for COPD across the 7MM, 2018-2028
  • Table 28: High-Prescribing Physicians (non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for COPD in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in COPD for the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of COPD During the Forecast Period
  • Figure 4: Normal Lungs and Lungs with COPD
  • Figure 5: The Pathogenesis of COPD
  • Figure 6: Refined ABCD Assessment Tool for COPD, 2018
  • Figure 7: 7MM, Total Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 8: 7MM, Diagnosed Prevalence of COPD, Men and Women, Ages ≥35 Years, 2018
  • Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of COPD
  • Figure 10: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of COPD
  • Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD by Severity
  • Figure 12: 7MM, Total Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 13: 7MM, Total Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 14: 7MM, Total Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 15: 7MM, Diagnosed Prevalent Cases of COPD, Men and Women, Ages ≥35 Years
  • Figure 16: 7MM, Diagnosed Prevalent Cases of COPD, by Sex, Ages ≥35 Years, 2018
  • Figure 17: 7MM, Diagnosed Prevalent Cases of COPD by Age, Men and Women, 2018
  • Figure 18: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 19: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2011 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 20: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using mMRC Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 21: 7MM, Diagnosed Prevalent Cases of COPD by Severity (Using CAT Scores - GOLD 2016 Criteria), Men and Women, Ages ≥35 Years, 2018
  • Figure 22: COPD Treatment Algorithm
  • Figure 23: Unmet Needs and Opportunities in COPD
  • Figure 24: Overview of the Development Pipeline in COPD
  • Figure 25: Key Phase II/III Trials for Promising Pipeline Agents
  • Figure 26: Competitive Assessment of Late-Stage Pipeline Agents for COPD
  • Figure 27: Analysis of the Company Portfolio Gap in COPD During the Forecast Period
  • Figure 28: Global Sales for COPD by Country, 2018 and 2028
  • Figure 29: Sales for COPD by Drug Class in the US, 2018 and 2028
  • Figure 30: Sales for COPD by Drug Class in the 5EU, 2018 and 2028
  • Figure 31: Sales for COPD by Drug Class in Japan, 2018 and 2028
目次
Product Code: GDHC188PIDR

Chronic obstructive pulmonary disease (COPD) is a common, preventable, incurable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation. Long-term exposure to noxious particles or gases such as cigarette smoke and environmental pollution can induce chronic inflammation in the airways, subsequently causing alveolar abnormalities. Pro-inflammatory cytokines, which are secreted from immune cells such as neutrophils, macrophages, and B cells, and CD4+ and CD8+ T lymphocyte infiltration in the lungs, in addition to elastases, can cause destruction and dysfunction within the airways.

This leads to airflow limitation and causes structural abnormalities such as obstructive bronchiolitis and parenchymal destruction (emphysema). In turn, these changes reduce lung elastic recoil and therefore the ability of the airways to remain open during expiration. Symptoms from such changes include dyspnea, wheezing, chronic cough, and sputum over production, which can impact a patient's physical and mental well-being. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease.

Key Highlights

  • During the 10-year forecast period, there are 7 pipeline products that are on track to launch, driving a forecast growth in the 7MM from $10.9B in 2018 to $19.3B in 2028, which represents a CAGR of 5.9%.
  • The percentage of drug-treated patients (receiving maintenance treatment only) will rise across the 7MM with an average AGR of 1.19% across all COPD severity grades, reaching over 23 million by 2028.
  • The entry of inhaled corticosteroids/long-acting beta2-agonists/long-acting muscarinic antagonists (ICS/LABA/LAMA) that will include expensive bronchodilators, will continue to take patient share from LABA and LAMA monotherapies, and ICS/LABA dual therapy to simplify treatment management.
  • The entry of anti-eosinophilic biologics from 2024 will boost overall COPD sales despite the small patient population that these therapies will treat. These therapies are only suitable for COPD patients with high levels of eosinophilia, but hold a high price tag.

Key Questions Answered

  • How will the COPD market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2018-2028?
  • What are the most promising late-stage pipeline products for COPD?
  • How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing COPD product options?
  • What are the remaining unmet needs in COPD?
  • What drivers and barriers will affect COPD product sales in the 7MM over the forecast period?

Scope

  • Overview of COPD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline COPD market revenue from 2018-2028. Annual cost of treatment and major pipeline product sales in this forecast period are included.
  • Key topics covered include current COPD treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD product sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global COPD market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global COPD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • I dentify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 COPD: Executive Summary

  • 2.1 Sales for COPD by Country, 2018-2028
  • 2.2 GSK continues to dominate the COPD market in 2028
  • 2.3 Despite the Variety of Available Therapies, COPD Remains a Market with High Unmet Need
  • 2.4 Treatments that Reverse the Progression of COPD Remain Elusive
  • 2.5 Pipeline COPD Treatment to Target a Niche Population
  • 2.6 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Symptoms

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for COPD (2018 - 2028)
    • 5.5.1 Total Prevalent Cases of COPD
    • 5.5.2 Sex-Specific Total Prevalent Cases of COPD
    • 5.5.3 Age-Specific Total Prevalent Cases of COPD
    • 5.5.4 Diagnosed Prevalent Cases of COPD
    • 5.5.5 Sex-Specific Diagnosed Prevalent Cases of COPD
    • 5.5.6 Age-Specific Diagnosed Prevalent Cases of COPD
    • 5.5.7 Diagnosed Prevalent Cases of COPD by Severity
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Disease-Modifying Treatments to Reverse the Progression of COPD
  • 8.3 Identification of Biomarkers that Predict Efficacy
  • 8.4 Observance of GOLD Guidelines Among General Practitioners
  • 8.5 Improved Clinical Trial Design
  • 8.6 Earlier Diagnosis and Recognition of Symptoms

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
    • 9.2.1 IL-4/IL-5 inhibitors
    • 9.2.2 IL-33 inhibitors
    • 9.2.3 PDE inhibitors
    • 9.2.4 CFTR modulators

10 Current and Future Players

11 Market Outlook

12 Appendix

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.